Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), James Larkin(Trinity College Dublin), Claus Garbe(University Children's Hospital Tübingen), Brigitte Dréno(Inserm), Mario Mandalà(University of Perugia), Lev Demidov(Heidelberg University), Luis de la Cruz‐Merino, Daniel O. Koralek, Grant A. McArthur(The University of Melbourne), Ilsung Chang, Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Daniil Stroyakovskiy(Shikoku Cancer Center), L. Thomas, Antoni Ribas(University of California, Los Angeles), Anna Maria Di Giacomo(University of Siena), Jessie J. Hsu, Gabrielle Liszkay(National Institute of Oncology), Victoria Atkinson(Greenslopes Private Hospital), Isabelle Rooney, Yibing Yan, Matthew Wongchenko
Cited by 1,005
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
|Journal of Clinical Investigation|2017|3.9k
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2019|3.7k